51037-30-0

51037-30-0 structure

Name: Acipimox
Chemical Name: 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
CAS Number: 51037-30-0
Molecular Formula: C₆H₆N₂O₃
Molecular Weight: 154.123
Catalog: API Circulatory system medication Regulating blood lipids
Create Date: 2018-04-29 08:00:00
Modify Date: 2024-01-03 13:49:51
Acipimox is a niacin derivative used as a hypolipidemic agent.Target: Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. From Wikipedia.

Name	5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
Synonyms	5-methyl-2-pyrazinoic-4-oxide 2-Pyrazinecarboxylic acid, 5-methyl-, 4-oxide 2-Carboxy-5-methylpyrazine 4-oxide,5-Methylpyrazinecarboxylic acid 4-oxide 5-Carboxy-2-methylpyrazine 1-oxide 5-methyl-4-oxy-pyrazine-2-carboxylic acid 5-methylpyrazine-2-carboxylic acid 4-oxide 2-carboxy-5-methylpyrazine 4-oxide Acipimox K-9321 Olbetam 5-Methylpyrazinecarboxylic acid 4-oxide 5-Methyl-2-pyrazinecarboxylic acid 4-oxide 2-methyl-5-pyrazinecarboxylic acid 1-oxide Olbemox EINECS 256-928-3 T6N DNJ AO B1 EVQ MFCD00865757

Description	Acipimox is a niacin derivative used as a hypolipidemic agent.Target: Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. From Wikipedia.
Related Catalog	Signaling Pathways >> Others >> Others Natural Products >> Alkaloid Research Areas >> Cardiovascular Disease
References	[1]. http://en.wikipedia.org/wiki/Acipimox

TOXIC EFFECTS :: Biochemical - Metabolism (Intermediary) - lipids including transport

REFERENCE :: EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 15,157,1980

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H319
Precautionary Statements	P305 + P351 + P338
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xi: Irritant;
Risk Phrases	R36
Safety Phrases	S26
RIDADR	NONH for all modes of transport
RTECS	UQ2453000
HS Code	2942000000

51037-35-5

51037-30-0

Literature: Carlo Erba S.p.A. Patent: US4002750 A1, 1977 ;

108-31-6

5521-55-1

51037-30-0

Literature: Carlo Erba S.p.A. Patent: US4002750 A1, 1977 ;

5521-55-1

7722-84-1

51037-30-0

Literature: Montedison S.p.A. Patent: US4866178 A1, 1989 ;

51037-25-3

51037-30-0

Literature: Ambrogi; Cozzi; Sanjust; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 157 - 163

5521-57-3

51037-30-0

Literature: Ambrogi; Cozzi; Sanjust; et al. European Journal of Medicinal Chemistry, 1980 , vol. 15, # 2 p. 157 - 163

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%